Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Greenacre and Pecora elected to NeoStem board

This article was originally published in Scrip

Executive Summary

NeoStem, a leader in the development and manufacture of cell therapies, has appointed Martyn Greenacre and Dr Andrew Pecora to its board. Mr Greenacre was previously chair of BMP Sunstone's board, and also served as a director of Cephalon. He is currently chair of the board of Acusphere and a director of Curis. From 1997 to 2001, Mr Greenacre was CEO and director of Delsys Pharmaceutical Corporation. Dr Pecora is co-founder and past chairman and CEO of PCT, now a NeoStem company. He currently serves as CMO of NeoStem, vice-president of cancer services and chief innovations officer of the John Theurer Cancer Center at Hackensack University Medical Center, and co-managing partner of the Northern Jersey Cancer Center.

You may also be interested in...



Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel